CAR T cell therapy for children with hard-to-treat leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 21 years old.
- Your leukemia must test positive for CD19, CD22, or both within the last 2 months, even after receiving other treatments targeting these markers.
- You must have had a second or later relapse, or a relapse after a stem cell transplant, or leukemia that did not go away with treatment.
- You must have a life expectancy greater than 12 weeks (for collection) and 8 weeks (for treatment).
- You must be in fairly good health, with a performance score of at least 50 (able to do most daily activities with some help).
- Your heart, kidneys, lungs, and liver must work well enough based on specific tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This trial tests a new CAR T cell treatment for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The goal is to see if this therapy is safe and can help control the cancer so a stem cell transplant may be possible.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.